Q2 INTERIM REPORT APRIL - JUNE 2022
READ MORE
Mentice acquires Ankyras solutions from Galgo Medical SL
READ MORE

Mentice publishes the company’s interim report for the period July–September 2020

Thursday, November 12, 2020

Two exciting acquisitions and strong performance in the medical device industry segment
 

Third quarter (July–September 2020)

  • Net sales amounted to 33.4 (29.3) MSEK.
  • Operating income for the period before depreciations (EBITDA) totalled 4.1 (-6.7) MSEK.
  • Net income for the period amounted to -0.3 (-9.0) MSEK.
  • Earnings per share (EPS) was -0.01 (-0.37) SEK.
  • Order intake amounted to 34.6 (24.4) MSEK.
  • Cash flow from operating activities totalled -6.2 (-16.2) MSEK.

First nine months of the year (January–September 2020)

  • Net sales for the first nine months of the year amounted to 91.6 (89.1) MSEK.
  • Operating income for the first nine months of the year before depreciations (EBITDA) totalled -8.3 (-24.7) MSEK.
  • Net income for the first nine months of the year amounted to -16.4 (-28.4) MSEK.
  • Earnings per share (EPS) for the first nine months of the year was -0.68 (-1.56) SEK.
  • Order intake for the first nine months of the year amounted to 95.5 (84.4) MSEK.
  • Cash flow from operating activities for the first nine months of the year totalled
    10.6 (-20.6) MSEK.

“In the third quarter, we were able to deliver overall encouraging financial performance considering the current circumstances, and strong performance from the Medical Device Industry segment with multiple larger orders received during the period. Furthermore, we conducted two exciting acquisitions, which were presented in early October,” says Göran Malmberg, CEO of Mentice AB (publ).

Webcast presentation of the interim report

Mentice's interim report for July–September 2020 will be presented by CEO Göran Malmberg with the possibility to ask questions on November 12, 2020 at 09:30 CET. The presentation will be held via the web and in English.

To register for the presentation, please visit: https://register.gotowebinar.com/register/8575874448186755597

Please make sure to register at least a few minutes in advance.

For more information, please contact:
Göran Malmberg, CEO, Mentice
E-post: 
goran.malmberg@mentice.com

US Mobile. +1 (312) 860 5610

Sweden Mobile +46 (0) 703 09 22 22

About Mentice

Mentice is the world leader in software and hardware simulation solutions for endovascular therapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular and peripheral interventions are just some of the clinical areas covered by our solutions. More information on www.mentice.com

This information is information that Mentice AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person, at 08.30 CET on November 12, 2020.  

Marketplace| Nasdaq First North Growth Market, Stockholm | Ticker symbol MNTC

Certified Adviser| FNCA Sweden AB, phone +46 8 528 00 399

DELÅRSRAPPORT Q2 APRIL - JUNI 2022
LÄS MER
Mentice förvärvar Ankyras från det spanska företaget Galgo Medical S.L.
LÄS MER

Mentice publishes the company’s interim report for the period July–September 2020

Thursday, November 12, 2020

Two exciting acquisitions and strong performance in the medical device industry segment
 

Third quarter (July–September 2020)

  • Net sales amounted to 33.4 (29.3) MSEK.
  • Operating income for the period before depreciations (EBITDA) totalled 4.1 (-6.7) MSEK.
  • Net income for the period amounted to -0.3 (-9.0) MSEK.
  • Earnings per share (EPS) was -0.01 (-0.37) SEK.
  • Order intake amounted to 34.6 (24.4) MSEK.
  • Cash flow from operating activities totalled -6.2 (-16.2) MSEK.

First nine months of the year (January–September 2020)

  • Net sales for the first nine months of the year amounted to 91.6 (89.1) MSEK.
  • Operating income for the first nine months of the year before depreciations (EBITDA) totalled -8.3 (-24.7) MSEK.
  • Net income for the first nine months of the year amounted to -16.4 (-28.4) MSEK.
  • Earnings per share (EPS) for the first nine months of the year was -0.68 (-1.56) SEK.
  • Order intake for the first nine months of the year amounted to 95.5 (84.4) MSEK.
  • Cash flow from operating activities for the first nine months of the year totalled
    10.6 (-20.6) MSEK.

“In the third quarter, we were able to deliver overall encouraging financial performance considering the current circumstances, and strong performance from the Medical Device Industry segment with multiple larger orders received during the period. Furthermore, we conducted two exciting acquisitions, which were presented in early October,” says Göran Malmberg, CEO of Mentice AB (publ).

Webcast presentation of the interim report

Mentice's interim report for July–September 2020 will be presented by CEO Göran Malmberg with the possibility to ask questions on November 12, 2020 at 09:30 CET. The presentation will be held via the web and in English.

To register for the presentation, please visit: https://register.gotowebinar.com/register/8575874448186755597

Please make sure to register at least a few minutes in advance.

For more information, please contact:
Göran Malmberg, CEO, Mentice
E-post: 
goran.malmberg@mentice.com

US Mobile. +1 (312) 860 5610

Sweden Mobile +46 (0) 703 09 22 22

About Mentice

Mentice is the world leader in software and hardware simulation solutions for endovascular therapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular and peripheral interventions are just some of the clinical areas covered by our solutions. More information on www.mentice.com

This information is information that Mentice AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person, at 08.30 CET on November 12, 2020.  

Marketplace| Nasdaq First North Growth Market, Stockholm | Ticker symbol MNTC

Certified Adviser| FNCA Sweden AB, phone +46 8 528 00 399